| Patent application number | Description | Published |
|---|
| 20080213363 | Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa - Compositions, methods, and formulations for delivering 5-HT | 09-04-2008 |
| 20080254101 | PILOCARPINE COMPOSITIONS AND METHODS OF USE THEREOF - The present invention provides novel compositions for the delivery of pilocarpine or a pharmaceutically acceptable salt thereof across the oral mucosa, preferably across the buccal mucosa. In particular, the buffer systems in the compositions of the present invention contain an amount of a strong base that is less than the amount of a weak base, thereby increasing the stability of compositions such as chewing gum compositions and raising the pH of saliva to a pH greater than about 7.5 to facilitate the substantially complete conversion of pilocarpine from its ionized to its un-ionized form. Methods for using the compositions of the present invention for treating conditions such as dry mouth are also provided. | 10-16-2008 |
| 20100113427 | COMPOSITIONS OF 5-HT3 ANTAGONISTS AND DOPAMINE D2 ANTAGONISTS FOR TREATMENT OF DOPAMINE-ASSOCIATED CHRONIC CONDITIONS - The present invention provides novel compositions comprising a combination of a 5-HT | 05-06-2010 |
| 20100113483 | COMPOSITIONS OF 5-HT3 ANTAGONISTS AND DOPAMINE D2 ANTAGONISTS FOR TREATMENT OF DOPAMINE-ASSOCIATED CHRONIC CONDITIONS - The present invention provides novel compositions comprising a combination of a 5-HT | 05-06-2010 |
| 20100240695 | STABILIZED ZOLPIDEM PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions for buccal delivery of zolpidem comprising an effective amount of zolpidem and a carbonate and bicarbonate buffer system in an amount sufficient to raise the pH of saliva to at least 8.5, and wherein the carbonate forms a coating on the bicarbonate wherein the amount of carbonate coating is at least 30% (w/w) of the total buffer amount are described. Pharmaceutical compositions for buccal delivery of zolpidem comprising an effective amount of zolpidem and a binary buffer system of carbonate and bicarbonate, wherein the carbonate and bicarbonate are co-located in a single particle, wherein the bicarbonate is coated with the carbonate, and wherein the amount of carbonate coating is at least 30% (w/w) of the binary buffer system are also described. | 09-23-2010 |
| 20100249177 | COMPOSITIONS AND METHODS FOR TREATING MIDDLE-OF-THE-NIGHT INSOMNIA - The present invention provides compositions for treating middle-of-the-night insomnia without residual sedative effects upon awakening by administering low doses (about 5 mg or less) of zolpidem or a salt thereof. | 09-30-2010 |
| 20100291004 | COMPOSITIONS FOR DELIVERING HYPNOTIC AGENTS ACROSS THE ORAL MUCOSA AND METHODS OF USE THEREOF - The present invention provides novel compositions for the delivery of a hypnotic agent across the oral mucosa. In particular, the buffer system in the compositions of the present invention raises the pH of saliva to a pH greater than about 7.8, thereby facilitating the substantially complete conversion of the hypnotic agent from its ionized to its un-ionized form. As a result, the dose of hypnotic agent is rapidly and efficiently absorbed by the oral mucosa with surprisingly low inter-subject variability. Furthermore, delivery of the hypnotic agent across the oral mucosa advantageously bypasses hepatic first pass metabolism of the drug and avoids enzymatic degradation of the drug within the gastrointestinal tract. Methods for using the compositions of the present invention for treating sleep disorders such as insomnia are also provided. | 11-18-2010 |
| 20100298397 | METHOD OF TREATMENT OF OBSESSIVE COMPULSIVE DISORDER WITH ONDANSETRON - Methods for treating obsessive compulsive disorder are described. In one method, a serotonin reuptake inhibitor (SRI) and ondansetron or a pharmaceutically acceptable salt thereof is administered to a patient suffering from obsessive compulsive disorder. The step of administering the SRI and the ondansetron is then repeated for more than seven days. In another method, an SRI, a neuroleptic, and ondansetron or a pharmaceutically acceptable salt thereof is administered to a patient suffering from obsessive compulsive disorder. The step of administering the SRI, the neuroleptic, and the ondansetron is then repeated for more than seven days. In another method, ondansetron or a pharmaceutically acceptable salt thereof is administered to a patient suffering from obsessive compulsive disorder for more than seven days. The ondansetron or pharmaceutically acceptable salt thereof may be administered as a pharmaceutically effective dose up to about 1.5 mg (free-base equivalent). | 11-25-2010 |
| 20110039881 | COMPOSITIONS AND METHODS FOR TREATING MIDDLE-OF-THE-NIGHT INSOMNIA - The present invention provides compositions and methods for treating middle-of-the-night insomnia without residual sedative effects upon awakening by dosing an amount of zolpidem or a salt thereof to a subject who awakens from sleep and desires to resume sleep for less than 5 hours. The step of dosing is performed after the subject awakens from sleep and the amount permits the subject to awaken at a time about four hours after dosing without residual sedative effects. | 02-17-2011 |
| 20110046117 | COMPOSITIONS OF 5-HT3 ANTAGONISTS AND DOPAMINE D2 ANTAGONISTS FOR TREATMENT OF DOPAMINE-ASSOCIATED CHRONIC CONDITIONS - The present invention provides novel compositions comprising a combination of a 5-HT | 02-24-2011 |
| 20110112116 | COMPOSITIONS OF 5-HT3 ANTAGONISTS AND DOPAMINE D2 ANTAGONISTS FOR TREATMENT OF DOPAMINE-ASSOCIATED CHRONIC CONDITIONS - Methods are provided for partial aortic obstruction for cerebral perfusion augmentation in patients suffering from global or focal cerebral ischemia. Alternatively, the methods can be used to partially obstruct aortic blood flow to condition the spinal cord to secrete neuroprotective agents prior to abdominal aortic aneurysm repair. Partial obstruction of a vessel can be accomplished by a device comprising an elongate catheter and a distally mounted expandable member. The expandable member may comprise one or two balloons. Other medical devices, such as an angioplasty, stent, or atherectomy catheter, can be inserted distal the expandable member to provide therapeutic intervention. | 05-12-2011 |
